


The Next Wave of iBio Innovation

Myostatin and Activin A Bispecific



Combined Myostatin and Activin A Antagonism

Synergistic Effect on Muscle Growth and Potential Treatment for Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)




We are developing bispecific **co-inhibitors of Myostatin and Activin A** designed to **enhance muscle growth** and **improve quality of weight loss** during and after treatment with incretin drugs


Why Myostatin & Activin A

- Myostatin and Activin A are **key negative regulators** of muscle mass
- Both are members of the TGF β superfamily
- Activin A mechanism is **pharmacologically validated**^{1, 2}
- **Combined** Activin A and Myostatin **inhibition**, **causes** more **pronounced muscle growth**³
- Myostatin and Activin A inhibition are believed to be **key features for treating PH-HFpEF**⁴


Binding of Myostatin and Activin A to cells leads to **muscle atrophy**



Simultaneous blocking of Myostatin and Activin A leads to **muscle growth**



iBio's Myostatin and Activin A Bi-Specific Targets Both Key Negative Muscle Regulators, Synergistically Increasing Muscle Mass



In Vitro Data

Only a Myostatin x Activin A bi-specific antibody fully blocks both muscle growth suppressors, enabling optimal growth, while single-target antibodies fall short

Increased muscle fusion index in human muscle stem cells is a surrogate of muscle growth

